2 stories tagged by Digg
World & Business
Bloomberg reports UniQure said AMT-130's benefits in a small trial were not as good after four years as after three. Barron's reports the company still sees a path to approval, even as its stock plunged 48%.
Science
STAT reports that the therapy's benefit was smaller than in a similar analysis from a year earlier, though it continued to slow progression at four years.
